Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 4,706 Jan 1 – Oct 27, 2026
- Disclosed funding
- $340.2B 3674 disclosed amounts
- Median round
- $14.5M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| KT Develops inhaled therapies for severe respiratory diseases | $103M | Series B | Biotech | United States | Investors | |
| VS Develops a ureteroscopic system for complete kidney stone clearance | $30M | Series A | Healthtech | United States | Investors | |
| R Provides enterprise-grade infrastructure for stablecoin-powered payments | $250M | Series CSeries C+ | Fintech | United States | Investors | |
| MM Major Medical DevicesCompany profile Develops innovative vascular intervention solutions for abdominal aortic aneurysms Develops innovative vascular intervention solutions for abdominal aortic aneurysms | Undisclosed | StrategicUndisclosed | Healthtech | United States | Investors | |
| B BradoCompany profile Provides Conversational Engagement Platform for patient navigation and engagement Provides Conversational Engagement Platform for patient navigation and engagement | Undisclosed | Undisclosed | Healthtech | United States | Investors | |
 MEDIPOSTCompany profile MEDIPOST develops stem-cell therapies derived from donated umbilical cord blood. MEDIPOST develops stem-cell therapies derived from donated umbilical cord blood. | $140M | Undisclosed | Biotech | United States | Investors | |
| CI Provides AI-native, full-stack insurance for startups | $108M | Series A | Fintech | United States | Investors | |
| b bit.bioCompany profile Creates functional, human-relevant cells and models for research, drug discovery, and development Creates functional, human-relevant cells and models for research, drug discovery, and development | $50M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
| H Builds highly automated factories producing defense and aerospace systems | Undisclosed | Undisclosed | Industrial tech | United States | Investors | |
 AirNexis TherapeuticsCompany profile AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01. AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01. | $200M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
BioStack, Tractian, Blacksmith
161rounds5led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
111rounds21led - 3General Catalyst
Matiks, Provision Labs, Tractian
102rounds13led - 4Lightspeed
Warp Sciences, Different, Zenzap
80rounds8led - 5Sequoia Capital
Nevis, Warhound, Whop
72rounds13led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →